HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Saúl Alberto Díaz-Pérez Selected Research

Ad5-nCoV vaccine

12/2022Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
9/2021Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Saúl Alberto Díaz-Pérez Research Topics

Disease

4COVID-19
06/2023 - 09/2021
1Rheumatoid Arthritis
12/2023
1Inflammation (Inflammations)
04/2023
1Mood Disorders (Mood Disorder)
04/2023
1Vitamin D Deficiency
04/2023
1Infections
09/2021

Drug/Important Bio-Agent (IBA)

4Neutralizing AntibodiesIBA
06/2023 - 09/2021
2BNT162 VaccineIBA
06/2023 - 01/2022
2VaccinesIBA
06/2023 - 01/2022
2AntibodiesIBA
06/2023 - 12/2022
2Ad5-nCoV vaccineIBA
12/2022 - 09/2021
1AutoantibodiesIBA
12/2023
1CytokinesIBA
04/2023
1Serotonin (5 Hydroxytryptamine)IBA
04/2023
1Vitamin DFDA LinkGeneric
04/2023
1sinovac COVID-19 vaccineIBA
12/2022
1COVID-19 VaccinesIBA
12/2022
1mRNA VaccinesIBA
12/2022
1Antidepressive Agents (Antidepressants)IBA
09/2021